What intervention for a 10-month-old with influenza (flu)?

From the Guidelines

Oseltamivir is the recommended treatment for a 10-month-old with influenza (flu).

Key Considerations

• The American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) recommend treatment with oseltamivir for children with serious, complicated, or progressive disease presumptively or definitively caused by influenza, irrespective of influenza vaccination status or whether illness began >48 hours before presentation 1.
• Children younger than 2 years are at an increased risk of hospitalization and complications attributable to influenza, making timely treatment crucial 1.
• The recommended dosage of oseltamivir for infants 9-11 months is 3.5 mg/kg per dose, twice daily, for 5 days 1.
• Treatment should be started as soon as possible after illness onset and should not be delayed while waiting for a definitive influenza test result, because early therapy provides the best outcomes 1.
• Clinical judgment is an important factor in treatment decisions for pediatric patients who present with influenza-like illness, taking into account underlying conditions, disease severity, time since symptom onset, and local influenza activity 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The AAP and CDC recommend oseltamivir treatment for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• No benefit exists for double-dose NAI therapy, compared to standard-dose therapy, on the basis of published data from a randomized prospective trial enrolling 75% of subjects younger than 15 years 1.
• The FDA has approved oseltamivir for treatment of children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe disease or with progressive disease has been shown to provide some benefit and should be offered 1.
• The FDA has licensed oseltamivir for children as young as 2 weeks of age, and given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment 1.
• Oseltamivir is available in capsule and oral suspension formulations, and the commercially manufactured liquid formulation has a concentration of 6 mg/mL 1.
• If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment outweigh the possible risks of treatment in pediatric patients, including those younger than 2 years 1.
• Vomiting is a common adverse effect of oseltamivir, occurring in approximately 5% of treated patients 1.
• Oseltamivir dosing for preterm infants is lower than for term infants, and preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group 1.
• Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provides the basis for dosing preterm infants using their postmenstrual age (gestational age + chronological age) 1.
• For extremely preterm infants (<28 weeks), consultation with a pediatric infectious diseases physician is recommended 1.
• Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm 1.
• The commercially manufactured oral suspension of oseltamivir has a concentration of 6 mg/mL, and if it is not available, a suspension can be compounded by retail pharmacies to a final concentration of 6 mg/mL 1.
• The benefits of oseltamivir treatment in reducing the duration of fever and illness symptoms, and the risks of complications, including those resulting in hospitalization and death, have been consistently demonstrated in available studies 1.
• The AAP, CDC, and Infectious Diseases Society of America recommend treatment with oseltamivir for children with presumed serious, complicated, or progressive disease, irrespective of influenza immunization status or whether illness began 48 hours before admission 1.
• Earlier treatment provides better clinical responses, but treatment after 48 hours of symptoms in adults and children with moderate to severe

From the Research

Intervention for a 10-month-old with Influenza (Flu)

• The American Academy of Pediatrics recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age 2, 3, 4.
• For a 10-month-old with influenza, antiviral treatment is recommended if they are hospitalized, have severe or progressive disease, or have underlying conditions that increase their risk of complications of influenza, regardless of duration of illness 2, 3, 5, 4.
• Antiviral treatment may be considered in the outpatient setting for symptomatic children with suspected or confirmed influenza disease who are not at high risk for influenza complications, if treatment can be initiated within 48 hours of illness onset 2, 3, 4.
• Antiviral treatment may also be considered for children with suspected or confirmed influenza disease whose siblings or household contacts either are younger than 6 months or have a high-risk condition that predisposes them to complications of influenza 2, 3, 4.
• Oseltamivir phosphate (Tamiflu) is an approved antiviral medication for the treatment of uncomplicated influenza in patients two weeks and older, including infants 6.
• Neuraminidase inhibitors, such as oseltamivir and zanamivir, can shorten illness duration, decrease symptom severity, and lower the risk of complications leading to hospitalization and death 5.